Ranolazine none I NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O |^1:0|

NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O |^1:0|

NBQX (20 mg/kg

The IC50 measured for radicle growth inhibition is 0

ONO5046-Na

Ranolazine none I NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O |^1:0|Ranolazine is an anti ischemic compound, which inhibits late sodium current that results in a reduction of Na+ dependent Ca2+ overload. Studies indicate that ATP production is shifted towards glucose oxidation by Ranolazine. This is due to the fact that more oxygen is required to phosphorylate the same amount of ATP during fatty acid oxidation than carbohydrate oxidation. These studies indicate that Ranolazine also inhibits oxygen consumption and